[Doubts as to the cardiovascular safety of rosiglitazone].
Wolffenbuttel
B H R
BH
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D005500:Follow-Up Studies; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000139:chemically induced* / Q000453:epidemiology; D000077154:Rosiglitazone; D012449:Safety; D045162:Thiazolidinediones / Q000009:adverse effects* / Q000627:therapeutic use; D013997:Time Factors
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone